Puma Biotechnology
PBYI
Market cap $172M

3.46 USD

+0.01

0.29%

At close Jul 15, 4:00 PM EDT

1 day

0.29%

5 days

-3.89%

1 month

0.29%

3 months

16.89%

6 months

12.70%

Year to date

10.90%

1 year

-5.46%

5 years

-64.94%

10 years

-96.77%

About: Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.

Employees: 172

Healthcare Biotechnology

0

Funds holding %

of 7,316 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

1,680% more call options, than puts

Call options by funds: $178K | Put options by funds: $10K

76% more repeat investments, than reductions

Existing positions increased: 44 | Existing positions reduced: 25

32% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 19

5% more funds holding

Funds holding: 111 [Q4 2024] → 116 (+5) [Q1 2025]

1.43% more ownership

Funds ownership: 59.88% [Q4 2024] → 61.31% (+1.43%) [Q1 2025]

0% more capital invested

Capital invested by funds: $89.7M [Q4 2024] → $90M (+$371K) [Q1 2025]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q4 2024] → 1 (+0) [Q1 2025]

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for PBYI.

See Analyst Rankings

Financial journalist opinion

Based on 7 articles about PBYI published over the past 30 days

Zacks Investment Research

Add These 4 Top-Ranked Liquid Stocks to Boost Portfolio Returns

INTU, NTGR, PBYI and DASH make the cut as top liquid stocks, with each boasting strong liquidity, growth attributes and operational efficiency.

Add These 4 Top-Ranked Liquid Stocks to Boost Portfolio Returns

Zacks Investment Research

Are Investors Undervaluing Puma Biotechnology (PBYI) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Are Investors Undervaluing Puma Biotechnology (PBYI) Right Now?

Zacks Investment Research

Why Fast-paced Mover Puma Biotech (PBYI) Is a Great Choice for Value Investors

If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Puma Biotech (PBYI) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.

Why Fast-paced Mover Puma Biotech (PBYI) Is a Great Choice for Value Investors

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology reported inducement restricted stock units awarded to new hires in June 2025, as required by Nasdaq Listing Rule 5635(c)(4).

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Zacks Investment Research

Is Puma Biotechnology (PBYI) Stock Undervalued Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Is Puma Biotechnology (PBYI) Stock Undervalued Right Now?

Puma Biotechnology: Updated Timelines And A Resurgence In Sentiment

Puma Biotechnology remains undervalued despite steady neratinib sales and a promising, though early-stage, pipeline. Neratinib's combination with trastuzumab deruxtecan shows intriguing signals, especially in pancreatic cancer, but pivotal data won't arrive until 2026. Alisertib's phase 2 trials in breast and lung cancer are ongoing, but lack of recent data keeps its potential speculative for now.

Puma Biotechnology: Updated Timelines And A Resurgence In Sentiment

Zacks Investment Research

Fast-paced Momentum Stock Puma Biotech (PBYI) Is Still Trading at a Bargain

Puma Biotech (PBYI) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.

Fast-paced Momentum Stock Puma Biotech (PBYI) Is Still Trading at a Bargain

Zacks Investment Research

Should Value Investors Buy Puma Biotechnology (PBYI) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Should Value Investors Buy Puma Biotechnology (PBYI) Stock?

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on June 2, 2025, the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit awards covering 18,250 shares of Puma common stock to three new non-executive employees. The awards were granted under Puma's 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity award.

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Zacks Investment Research

Why Fast-paced Mover Puma Biotech (PBYI) Is a Great Choice for Value Investors

If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Puma Biotech (PBYI) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.

Why Fast-paced Mover Puma Biotech (PBYI) Is a Great Choice for Value Investors

See News Rankings

Charts implemented using Lightweight Charts™